Overview: Plasmodium Falciparum Antigen TestIntroduction: The Plasmodium Falciparum Antigen Test detects Plasmodium falciparum to diagnose malaria, causing fever or fatigue, helping guide antimalarial treatment. Affecting 1 in 1,000 travelers to endemic areas, malaria poses diagnostic challenges due to rapid progression. Following 2023 World Health Organization (WHO) guidelines, it uses rapid antigen test for high accuracy, supporting parasitology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in infectious disease.
Other Names: P. falciparum Rapid Test, Malaria Antigen Assay.
FDA Status: FDA-approved test, meeting parasitology standards for diagnostic reliability.
Historical Milestone: Malaria antigen testing began in the 1990s with research by Moody, who developed rapid tests. Antigen test advancements in the 2000s by Abbott improved detection, surpassing earlier microscopy.
Purpose: Detects P. falciparum antigen presence to diagnose malaria, guides antimalarial therapy, and evaluates patients with fever, aiming to resolve symptoms.
Test Parameters: P. falciparum antigen presence
Pretest Condition: No special preparation required. Collect whole blood. Report travel history.
Specimen: Whole Blood (EDTA, 2-5 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document fever or fatigue. Include current medications or travel history.
Consent: Written consent required, detailing the test's purpose, infection risks (e.g., cerebral malaria), and sample collection risks.
Procedural Considerations: Uses rapid antigen test to detect parasite, requiring labs with test kits. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may alter detection, requiring correlation.
Clinical Significance: Positive antigen confirms malaria, guiding therapy. Early treatment might prevent complications, while untreated cases lead to death. Negative results may require other tests.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: Thick blood smear, PCR, or species identification to confirm diagnosis.
Test Limitations: Specific to P. falciparum; correlation with symptoms needed. False negatives possible with low parasitemia.
References: WHO Guidelines, 2023; Malaria Journal, Moody A, 2022.
